Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities.

World J Gastroenterol · 2021 · PMC8554408 · PMID 34754153

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

A recent patient-level meta-analysis has analyzed the efficacy of neoadjuvant FOLFIRINOX in BRPC, finding a favorable trend using FOLFIRINOX (median overall survival of 22 mo and median disease progression-free survival of 18.0 mo)[ 18 ].

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.